{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:49:17Z","timestamp":1761853757687,"version":"build-2065373602"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":118,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.nefroe.2021.10.007","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T07:13:45Z","timestamp":1636701225000},"page":"403-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intravenous iron in heart failure and chronic kidney disease"],"prefix":"10.1016","volume":"41","author":[{"given":"Patricia","family":"Carrilho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2021.10.007_bib0005","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1093\/ndt\/gft062","article-title":"Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"28","author":"Bailie","year":"2013","journal-title":"Nephrol Dial Transplant ."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0010","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1681\/ASN.2014090922","article-title":"Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis","volume":"26","author":"Charytan","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0015","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1053\/j.ajkd.2017.12.006","article-title":"Management of Heart Failure in Advancing CKD: Core Curriculum 2018","volume":"72","author":"House","year":"2018","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0020","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.amjcard.2013.11.061","article-title":"Quantification of Myocardial Iron Deficiency in Nonischemic Heart Failure by Cardiac T2* Magnetic Resonance Imaging","volume":"113","author":"Nagao","year":"2014","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0025","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/ejhf.640","article-title":"Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis","volume":"19","author":"Melenovsky","year":"2017","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0030","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jacc.2017.12.027","article-title":"The Burden of Iron Deficiency in Heart Failure: Therapeutic Approach","volume":"71","author":"Rocha","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0035","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0040","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0045","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency","volume":"136","author":"Van Veldhuisen","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0050","first-page":"269","article-title":"Impact of Cardiorenal Anemia Syndrome on Short- and Long-Term Clinical Outcomes in Patients Hospitalized with Heart Failure","volume":"040","author":"Joon","year":"2016","journal-title":"Cardiorenal Med."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0055","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/ndt\/18.1.141","article-title":"The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron","volume":"18","author":"Silverberg","year":"2003","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0060","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0735-1097(00)00613-6","article-title":"The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations","volume":"35","author":"Silverberg","year":"2000","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0065","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0735-1097(01)01248-7","article-title":"The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study","volume":"37","author":"Silverberg","year":"2001","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0070","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jacc.2006.11.024","article-title":"Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure: A Randomized, Double-Blind","volume":"49","author":"Ponikowski","year":"2007","journal-title":"Placebo-Controlled Trial. J Am Coll Cardiol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0075","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.repc.2013.06.003","article-title":"Anemia e defici\u00eancia de ferro na insufici\u00eancia card\u00edaca","volume":"33","author":"Gil VM.","year":"2014","journal-title":"Rev Port Cardiol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0085","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0090","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0095","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0100","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.ijcard.2013.04.181","article-title":"IRON-HF study: A randomized trial to assess the effects of iron in heart failure patients with anemia","volume":"168","author":"Beck-da-Silva","year":"2013","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency: FERRIC-HF: A Randomized, Controlled","volume":"51","author":"Okonko","year":"2008","journal-title":"Observer-Blinded Trial. J Am Coll Cardiol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0110","doi-asserted-by":"crossref","first-page":"74","DOI":"10.15420\/cfr.2019.3.2","article-title":"The Limitations of Symptom-based Heart Failure Management","volume":"5","author":"Papadimitriou","year":"2019","journal-title":"Card Fail Rev."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0115","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ejhf.473","article-title":"Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials","volume":"18","author":"Jankowska","year":"2016","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0120","first-page":"151","article-title":"The Efficacy and Safety of Iron Supplementation in Patients With Heart Failure and Iron Deficiency: A Systematic Review and Meta-analysis","volume":"32","author":"Qian","year":"2016","journal-title":"Can J Cardiol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.15420\/cfr.2018:6:2","article-title":"Iron Therapy in Heart Failure: Ready for Primetime?","volume":"4","author":"Mordi","year":"2018","journal-title":"Card Fail Rev."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0130","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0135","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J."},{"journal-title":"Effect of HDL-Raising Drugs on Cardiovascular Outcomes?: A Systematic Effect of HDL-Raising Drugs on Cardiovascular Outcomes?: A Systematic Review and Meta-Regression.","year":"2014","author":"Kaur","key":"10.1016\/j.nefroe.2021.10.007_bib0140"},{"key":"10.1016\/j.nefroe.2021.10.007_bib0145","article-title":"Prophylactic lidocaine for myocardial infarction","author":"Mart\u00ed-Carvajal","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0150","doi-asserted-by":"crossref","unstructured":"Hershko C. Mechanism of Iron Toxicity. Food Nutr Bull. 2007; 28(4_suppl4):S500-S509, doi:10.1177\/15648265070284S403.","DOI":"10.1177\/15648265070284S403"},{"key":"10.1016\/j.nefroe.2021.10.007_bib0155","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/ijms17010130","article-title":"Iron Homeostasis in Health and Disease","volume":"17","author":"Gozzelino","year":"2016","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0160","doi-asserted-by":"crossref","first-page":"351","DOI":"10.5935\/0101-2800.20160053","article-title":"an important iron metabolism regulator in chronic kidney disease","volume":"38","author":"Antunes","year":"2016","journal-title":"J Bras Nefrol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0165","doi-asserted-by":"crossref","first-page":"C450","DOI":"10.1152\/ajpcell.00348.2013","article-title":"Functional properties of human ferroportin , a cellular iron exporter reactive also with cobalt and zinc","volume":"306","author":"Mitchell","year":"2014","journal-title":"Am J Physiol Cell Physiol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0170","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.freeradbiomed.2018.07.003","article-title":"Erythropoietic regulators of iron metabolism","volume":"133","author":"Ganz","year":"2019","journal-title":"Free Radic Biol Med."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0175","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2215\/CJN.05931108","article-title":"Hepcidin - A potential novel biomarker for iron status in chronic kidney disease","volume":"4","author":"Zaritsky","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0180","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/eurheartj\/ehs377","article-title":"Iron status in patients with chronic heart failure","volume":"34","author":"Jankowska","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0185","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/ndt\/gfr431","article-title":"Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: A cross-sectional study","volume":"27","author":"Uehata","year":"2012","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0190","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency the IRONOUT HF randomized clinical trial","volume":"317","author":"Lewis","year":"2017","journal-title":"JAMA - J Am Med Assoc."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0195","article-title":"FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0200","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ki.2015.163","article-title":"A randomized trial of intravenous and oral iron in chronic kidney disease","volume":"88","author":"Agarwal","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0205","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1111\/hdi.12561","article-title":"Iron deficiency anemia in chronic kidney disease: Uncertainties and cautions","volume":"21","author":"Agarwal","year":"2017","journal-title":"Hemodial Int."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0210","doi-asserted-by":"crossref","unstructured":"Chapter 2: Use of iron to treat anemia in CKD. Kidney Int Suppl. 2012; 2(4):292-298, doi:10.1038\/kisup.2012.34.","DOI":"10.1038\/kisup.2012.34"},{"key":"10.1016\/j.nefroe.2021.10.007_bib0215","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12882-018-1119-7","article-title":"Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015)","volume":"19","author":"Park","year":"2018","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0220","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/ndt\/gft269","article-title":"Iron toxicity: Relevance for dialysis patients","volume":"29","author":"Fishbane","year":"2014","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0225","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.2215\/CJN.09510914","article-title":"Intravenous iron exposure and outcomes in patients on hemodialysis","volume":"9","author":"Fishbane","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0230","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12882-017-0513-x","article-title":"Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study","volume":"18","author":"Peters","year":"2017","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0235","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ki.2014.275","article-title":"Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality","volume":"87","author":"Bailie","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2012.01.015","article-title":"Hemodialysis-associated Hemosiderosis in the Era of Erythropoiesis- stimulating Agents: A MRI Study","volume":"125","author":"Rostoker","year":"2012","journal-title":"Am J Med."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0245","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1523-1755.2004.00480.x","article-title":"Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients","volume":"65","author":"Canavese","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0250","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2215\/CJN.04190510","article-title":"Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease","volume":"6","author":"Ferrari","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"issue":"Supplement 1","key":"10.1016\/j.nefroe.2021.10.007_bib0255","first-page":"2016","article-title":"Factors associated with themagnetic resonance imaging estimated liver concentration in long-term hemodialysis patientes receiving intravenous iron supplementation","volume":"31","author":"Castillo","year":"2016","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0260","article-title":"Liver Iron Content by MRI at the Start of Hemodialysis","volume":"112","author":"Carrilho","year":"2017","journal-title":"J Nephrol Urol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0265","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/ndt\/gfu104","article-title":"Iron dosing in kidney disease: Inconsistency of evidence and clinical practice","volume":"30","author":"Gaweda","year":"2015","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0270","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0275","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fphar.2014.00094","article-title":"Atherogenesis and iron: from epidemiology to cellular level","volume":"5","author":"Vinchi","year":"2014","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0280","doi-asserted-by":"crossref","unstructured":"Sato Y, Yanagita M. Immunology of the ageing kidney. Nat Rev Nephrol, doi:10.1038\/s41581-019-0185-9.","DOI":"10.1038\/s41581-019-0185-9"},{"key":"10.1016\/j.nefroe.2021.10.007_bib0285","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000484177","article-title":"Lymphocyte Cell Ratios and Mortality among Incident Hemodialysis Patients","volume":"46","author":"Catabay","year":"2017","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0290","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2369-11-16","article-title":"Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival","volume":"11","author":"Gupta","year":"2010","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0295","first-page":"1","article-title":"Physiological implications of NTBI uptake by T lymphocytes","author":"Pinto","year":"2014","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079870","article-title":"Non-transferrin-bound iron (NTBI) uptake by T lymphocytes: Evidence for the selective acquisition of oligomeric ferric citrate species","volume":"8","author":"Arezes","year":"2013","journal-title":"PLoS One."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0305","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1161\/01.STR.0000114875.31599.1C","article-title":"Association between High Serum Ferritin Levels and Carotid Atherosclerosis in the Study of Health in Pomerania (SHIP)","volume":"35","author":"Wolff","year":"2004","journal-title":"Stroke."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0310","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1536\/ihj.46.255","article-title":"Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease","volume":"46","author":"Reis","year":"2005","journal-title":"Int Heart J."},{"issue":"FEB","key":"10.1016\/j.nefroe.2021.10.007_bib0315","first-page":"2014","article-title":"The importance of iron in pathophysiologic conditions","volume":"6","author":"Gozzelino","year":"2015","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0320","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1038\/s41598-017-04664-y","article-title":"Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192895","article-title":"Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis","volume":"13","author":"Major","year":"2018","journal-title":"PLoS One."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0330","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2215\/CJN.01870408","article-title":"Low bone volume--a risk factor for coronary calcifications in hemodialysis patients","volume":"4","author":"Adragao","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0335","first-page":"113","article-title":"Regulation of erythropoietin production and recent trends in anaemia therapy","volume":"29","author":"Almeida","year":"2015","journal-title":"Port J Nephrol Hypert."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules22040598","article-title":"Non-anticoagulant heparins are hepcidin antagonists for the treatment of anemia","volume":"22","author":"Poli","year":"2017","journal-title":"Molecules."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0345","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/ndt\/gfg493","article-title":"Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients","volume":"19","author":"Kalantar-Zadeh","year":"2004","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0350","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1093\/ndt\/gfy190","article-title":"Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study","volume":"33","author":"Karaboyas","year":"2018","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0355","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/1744-9987.12378","article-title":"An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013)","volume":"19","author":"Masakane","year":"2015","journal-title":"Ther Apher Dial."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0360","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1681\/ASN.2005040423","article-title":"Time-dependent associations between iron and mortality in hemodialysis patients","volume":"16","author":"Kalantar-Zadeh","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0365","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0370","first-page":"1","author":"Robinson","year":"2017","journal-title":"Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice?: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0375","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000444335","article-title":"Annual Iron Loss Associated with Hemodialysis","volume":"43","author":"Tsukamoto","year":"2016","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0380","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41581-019-0128-5","article-title":"PIVOTAL trial: iron loading improves clinical outcomes","volume":"15","author":"Coyne","year":"2019","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.nefroe.2021.10.007_bib0385","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2019121340","article-title":"The Value of Intravenous Iron: Beyond the Cave of Speculation","author":"Coyne","year":"2020","journal-title":"J Am Soc Nephrol."}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251421000973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251421000973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:46:35Z","timestamp":1761853595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251421000973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2013251421000973"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2021.10.007","relation":{},"ISSN":["2013-2514"],"issn-type":[{"type":"print","value":"2013-2514"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous iron in heart failure and chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2021.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}